{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:17:12Z","timestamp":1784809032136,"version":"3.55.0"},"reference-count":51,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Immunol. Ther. Exp."],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00005-017-0484-4","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T07:18:00Z","timestamp":1501831080000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB\/c Mice"],"prefix":"10.2478","volume":"66","author":[{"given":"Nahid","family":"Maspi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ghaffarifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolhossein","family":"Dalimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Saaid","family":"Dayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"484_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cimid.2017.02.001","volume":"51","author":"A Abdoli","year":"2017","unstructured":"Abdoli A, Maspi N, Ghaffarifar F (2017) Wound healing in cutaneous leishmaniasis: a double edged sword of IL-10 and TGF-\u03b2. Comp Immunol Microbiol Infect Dis 51:15\u201326","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"484_CR2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vaccine.2008.10.013","volume":"27","author":"SB Ahmed","year":"2009","unstructured":"Ahmed SB, Touihri L, Chtourou Y et al (2009) DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB\/c mice. Vaccine 27:99\u2013106","journal-title":"Vaccine"},{"key":"484_CR3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.10.2.298","volume":"10","author":"J Alvar","year":"1997","unstructured":"Alvar J, Canavate C, Gutierrez-Solar B et al (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10:298\u2013319","journal-title":"Clin Microbiol Rev"},{"key":"484_CR4","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J, V\u00e9lez ID, Bern C et al (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7:e35671","journal-title":"PLoS ONE"},{"key":"484_CR5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"key":"484_CR6","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1128\/IAI.70.6.2828-2836.2002","volume":"70","author":"A Campos-Neto","year":"2002","unstructured":"Campos-Neto A, Webb JR, Greeson K et al (2002) Vaccination with plasmid DNA encoding TSA\/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB\/c mice. Infect Immun 70:2828\u20132836","journal-title":"Infect Immun"},{"key":"484_CR7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-3024.2009.01148.x","volume":"31","author":"FP Carneiro","year":"2009","unstructured":"Carneiro FP, De Magalhaes AV, De Jesus Abreu Almeida Couto M et al (2009) Foxp3 expression in lesions of the different clinical forms of American tegumentary leishmaniasis. Parasite Immunol 31:646\u2013651","journal-title":"Parasite Immunol"},{"key":"484_CR8","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/IAI.71.7.3988-3994.2003","volume":"71","author":"EA Coelho","year":"2003","unstructured":"Coelho EA, Tavares CA, Carvalho FA et al (2003) Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71:3988\u20133994","journal-title":"Infect Immun"},{"key":"484_CR9","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","volume":"70","author":"RN Coler","year":"2002","unstructured":"Coler RN, Skeiky YAW, Bernards K et al (2002) Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70:4215\u20134225","journal-title":"Infect Immun"},{"key":"484_CR10","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","volume":"75","author":"RN Coler","year":"2007","unstructured":"Coler RN, Goto Y, Bogatzki L et al (2007) Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 75:4648\u20134654","journal-title":"Infect Immun"},{"key":"484_CR11","doi-asserted-by":"crossref","first-page":"234ra56","DOI":"10.1126\/scitranslmed.3008222","volume":"6","author":"S Das","year":"2014","unstructured":"Das S, Freier A, Boussoffara T et al (2014) Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med 6:234ra56","journal-title":"Sci Transl Med"},{"key":"484_CR12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/biohorizons\/hzp004","volume":"2","author":"N Dunning","year":"2009","unstructured":"Dunning N (2009) Leishmania vaccines: from leishmanization to the era of DNA technology. Biosci Horizons 2:73\u201382","journal-title":"Biosci Horizons"},{"key":"484_CR13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0463.2012.02968.x","volume":"121","author":"F Ghaffarifar","year":"2013","unstructured":"Ghaffarifar F, Jorjani O, Sharifi Z et al (2013) Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major. APMIS 121:290\u2013298","journal-title":"APMIS"},{"key":"484_CR14","first-page":"CD004834","volume":"2","author":"U Gonzalez","year":"2009","unstructured":"Gonzalez U, Pinart M, Rengifo-Pardo M et al (2009) Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2:CD004834","journal-title":"Cochrane Database Syst Rev"},{"key":"484_CR15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/CVI.05024-11","volume":"18","author":"Y Goto","year":"2011","unstructured":"Goto Y, Bhatia A, Raman VS et al (2011) KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol 18:1118\u20131124","journal-title":"Clin Vaccine Immunol"},{"key":"484_CR16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","volume":"186","author":"S Gurunathan","year":"1997","unstructured":"Gurunathan S, Sacks DL, Brown DR et al (1997) Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186:1137\u20131147","journal-title":"J Exp Med"},{"key":"484_CR17","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","volume":"18","author":"S Gurunathan","year":"2000","unstructured":"Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927\u2013974","journal-title":"Annu Rev Immunol"},{"key":"484_CR18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.169.1.59","volume":"169","author":"FP Heinzel","year":"1989","unstructured":"Heinzel FP, Sadick MD, Holaday BJ et al (1989) Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 169:59\u201372","journal-title":"J Exp Med"},{"key":"484_CR19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2230.2000.00664.x","volume":"25","author":"NC Hepburn","year":"2000","unstructured":"Hepburn NC (2000) Cutaneous leishmaniasis. Clin Exp Dermatol 25:363\u2013370","journal-title":"Clin Exp Dermatol"},{"key":"484_CR20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1995-7645(14)60166-8","volume":"7","author":"HZ Hezarjaribi","year":"2014","unstructured":"Hezarjaribi HZ, Ghaffarifar F, Dalimi A et al (2014) Evaluation of protective effect of IL-22 and IL-12 on cutaneous leishmaniasis in BALB\/c mice. Asian Pac J Trop Med 7:940\u2013945","journal-title":"Asian Pac J Trop Med"},{"key":"484_CR21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-0556-2-17","volume":"2","author":"C Ivory","year":"2004","unstructured":"Ivory C, Chadee K (2004) DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther 2:17","journal-title":"Genet Vaccines Ther"},{"key":"484_CR22","first-page":"37","volume":"8","author":"O Jorjani","year":"2012","unstructured":"Jorjani O, Ghaffarifar F, Sharifi Z et al (2012) Cloning and expression of recombinant plasmid containing LACK gene of Leishmania major (MHRO\/IR\/75\/ER) in CHO cells. ISESCO J Sci Technol 8:37\u201343","journal-title":"ISESCO J Sci Technol"},{"key":"484_CR23","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1371\/journal.pntd.0001171","volume":"5","author":"GK Katara","year":"2011","unstructured":"Katara GK, Ansari NA, Verma S et al (2011) Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. PLoS Negl Trop Dis 5:e1171","journal-title":"PLoS Negl Trop Dis"},{"issue":"Suppl","key":"484_CR24","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1017\/S0031182006001831","volume":"133","author":"L Kedzierski","year":"2006","unstructured":"Kedzierski L, Zhu Y, Handman E (2006) Leishmania vaccines: progress and problems. Parasitology 133(Suppl):S87\u2013112","journal-title":"Parasitology"},{"key":"484_CR25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/092986709787458489","volume":"16","author":"L Kedzierski","year":"2009","unstructured":"Kedzierski L, Sakthianandeswaren A, Curtis JM et al (2009) Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16:599\u2013614","journal-title":"Curr Med Chem"},{"key":"484_CR26","first-page":"173","volume":"48","author":"K Kemp","year":"2000","unstructured":"Kemp K (2000) Cytokine-producing T cell subsets in human leishmaniasis. Arch Immunol Ther Exp 48:173\u2013176","journal-title":"Arch Immunol Ther Exp"},{"key":"484_CR27","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1016\/j.vaccine.2005.02.015","volume":"23","author":"A Khamesipour","year":"2005","unstructured":"Khamesipour A, Dowlati Y, Asilian A et al (2005) Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23:3642\u20133648","journal-title":"Vaccine"},{"key":"484_CR28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","volume":"9","author":"MA Kutzler","year":"2008","unstructured":"Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9:776\u2013788","journal-title":"Nat Rev Genet"},{"issue":"Suppl 1","key":"484_CR29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1179\/000349803225002606","volume":"97","author":"F Laguna","year":"2003","unstructured":"Laguna F (2003) Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 97(Suppl 1):135\u2013142","journal-title":"Ann Trop Med Parasitol"},{"key":"484_CR30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","volume":"239","author":"MA Liu","year":"2011","unstructured":"Liu MA (2011) DNA vaccines: an historical perspective and view to the future. Immunol Rev 239:62\u201384","journal-title":"Immunol Rev"},{"key":"484_CR31","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1016\/S0167-5699(05)80017-9","volume":"12","author":"RM Locksley","year":"1991","unstructured":"Locksley RM, Scott P (1991) Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol Today 12:A58\u2013A61","journal-title":"Immunol Today"},{"key":"484_CR32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/14760584.7.2.175","volume":"7","author":"S Lu","year":"2008","unstructured":"Lu S, Wang S, Grimes-Serrano JM (2008) Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 7:175\u2013191","journal-title":"Expert Rev Vaccines"},{"key":"484_CR33","first-page":"256","volume":"65","author":"N Maspi","year":"2015","unstructured":"Maspi N, Ghaffarifar F, Sharifi Z et al (2015) Cloning and constructing a plasmid encoding leishmania eukaryotic initiation factor gene of Leishmania major fused with green fluorescent protein gene as a vaccine candidate. West Indian Med J 65:256\u2013259","journal-title":"West Indian Med J"},{"key":"484_CR34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/20477724.2016.1232042","volume":"110","author":"N Maspi","year":"2016","unstructured":"Maspi N, Abdoli A, Ghaffarifar F (2016a) Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review. Pathog Glob Health 110:247\u2013260","journal-title":"Pathog Glob Health"},{"key":"484_CR35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/pim.12310","volume":"38","author":"N Maspi","year":"2016","unstructured":"Maspi N, Ghaffarifar F, Sharifi Z et al (2016b) Codelivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB\/c mice. Parasite Immunol 38:228\u2013235","journal-title":"Parasite Immunol"},{"key":"484_CR36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/apm.12651","volume":"125","author":"N Maspi","year":"2017","unstructured":"Maspi N, Ghaffarifar F, Sharifi Z et al (2017) Immunogenicity and efficacy of a bivalent DNA vaccine containing LeIF and TSA genes against murine cutaneous leishmaniasis. APMIS 125:249\u2013258","journal-title":"APMIS"},{"key":"484_CR37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.immuni.2008.11.013","volume":"30","author":"JB McLachlan","year":"2009","unstructured":"McLachlan JB, Catron DM, Moon JJ et al (2009) Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity 30:277\u2013288","journal-title":"Immunity"},{"key":"484_CR38","doi-asserted-by":"crossref","first-page":"e0003914","DOI":"10.1371\/journal.pntd.0003914","volume":"9","author":"R Miura","year":"2015","unstructured":"Miura R, Kooriyama T, Yoneda M et al (2015) Efficacy of recombinant canine distemper virus expressing Leishmania antigen against Leishmania challenge in dogs. PLoS Negl Trop Dis 9:e0003914","journal-title":"PLoS Negl Trop Dis"},{"key":"484_CR39","first-page":"377","volume":"76","author":"A Nadim","year":"1983","unstructured":"Nadim A, Javadian E, Tahvildar-Bidruni G et al (1983) Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 76:377\u2013383","journal-title":"Bull Soc Pathol Exot Filiales"},{"key":"484_CR40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4161\/hv.5.5.7607","volume":"5","author":"I Okwor","year":"2009","unstructured":"Okwor I, Uzonna J (2009) Vaccines and vaccination strategies against human cutaneous leishmaniasis. Hum Vaccines 5:291\u2013301","journal-title":"Hum Vaccines"},{"key":"484_CR41","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1086\/420792","volume":"189","author":"M Premenko-Lanier","year":"2004","unstructured":"Premenko-Lanier M, Rota PA, Rhodes GH et al (2004) Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J Infect Dis 189:2064\u20132071","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"484_CR42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1179\/000349803225002507","volume":"97","author":"A Rabello","year":"2003","unstructured":"Rabello A, Orsini M, Disch J (2003) Leishmania\/HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 97(Suppl 1):17\u201328","journal-title":"Ann Trop Med Parasitol"},{"key":"484_CR43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","volume":"7","author":"R Reithinger","year":"2007","unstructured":"Reithinger R, Dujardin JC, Louzir H et al (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7:581\u2013596","journal-title":"Lancet Infect Dis"},{"key":"484_CR44","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","volume":"2","author":"D Sacks","year":"2002","unstructured":"Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2:845\u2013858","journal-title":"Nat Rev Immunol"},{"key":"484_CR45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0738-081X(99)00047-4","volume":"17","author":"SM Salman","year":"1999","unstructured":"Salman SM, Rubeiz NG, Kibbi AG (1999) Cutaneous leishmaniasis: clinical features and diagnosis. Clin Dermatol 17:291\u2013296","journal-title":"Clin Dermatol"},{"key":"484_CR46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri.2016.72","volume":"16","author":"P Scott","year":"2016","unstructured":"Scott P, Novais FO (2016) Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol 16:581\u2013592","journal-title":"Nat Rev Immunol"},{"key":"484_CR47","first-page":"30","volume":"2","author":"F Tabatabaie","year":"2007","unstructured":"Tabatabaie F, Ghaffarifar F, Dalimi A et al (2007) Cloning and sequencing of Leishmania major thiol-specific-antioxidant antigen (TSA) gene. Iran J Parasitol 2:30\u201341","journal-title":"Iran J Parasitol"},{"key":"484_CR48","doi-asserted-by":"crossref","first-page":"e8974","DOI":"10.5812\/jjm.8974","volume":"7","author":"F Tabatabaie","year":"2014","unstructured":"Tabatabaie F, Mahdavi M, Faezi S et al (2014) Th1 platform immune responses against Leishmania major induced by thiol-specific antioxidant-based DNA vaccines. Jundishapur J Microbiol 7:e8974","journal-title":"Jundishapur J Microbiol"},{"issue":"Suppl 2","key":"484_CR49","first-page":"S93","volume":"24","author":"H Talat","year":"2014","unstructured":"Talat H, Attarwala S, Saleem M (2014) Cutaneous Leishmaniasis with HIV. J Coll Phys Surg Pak 24(Suppl 2):S93\u2013S95","journal-title":"J Coll Phys Surg Pak"},{"key":"484_CR50","first-page":"49","volume-title":"New technical report series on the control of leishmaniasis","author":"WHO","year":"2010","unstructured":"WHO (2010) New technical report series on the control of leishmaniasis. WHO, Geneva, pp 49\u201364"},{"key":"484_CR51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/vaccines1030225","volume":"1","author":"JA Williams","year":"2013","unstructured":"Williams JA (2013) Vector design for improved DNA vaccine efficacy, safety and production. Vaccines 1:225\u2013249","journal-title":"Vaccines"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00005-017-0484-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-017-0484-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-017-0484-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T20:49:00Z","timestamp":1704228540000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00005-017-0484-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1007\/s00005-017-0484-4","relation":{},"ISSN":["0004-069X","1661-4917"],"issn-type":[{"value":"0004-069X","type":"print"},{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,4]]}}}